SCHEMBL18301080

SCHEMBL18301080

COC(=O)C(=CO)Oc1ccccc1Br

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LY96 Q9Y6Y9 1/20 0.40
KMT2A Q03164 5/20 0.36
HTT P42858 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
NCEH1 Q6PIU2 1/20 0.36
PKM P14618 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
USP2 O75604 1/20 0.35
MAPT P10636 1/20 0.35
MEN1 O00255 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GRM4 Q14833 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18311967 1.00 LY96 (0.40) LY96KMT2AHTTKDM4EHPGD
SCHEMBL28268091 0.86 LY96 (0.39) LY96KMT2AHTTKDM4EHPGD
SCHEMBL18397751 0.84 LY96 (0.38) LY96KMT2AHTTKDM4EHPGD
SCHEMBL28269479 0.84 CYP11B1 (0.46) LY96KMT2AKDM4ENCEH1PKM
SCHEMBL18397749 0.84 LY96 (0.38) LY96KMT2AHTTKDM4EHPGD
SCHEMBL20225562 0.79 KMT2A (0.39) KMT2AKDM4EPKMNPC1RAB9A
SCHEMBL7802444 0.79 KDM4E (0.43) KMT2AKDM4EHPGDPKMNPC1
SCHEMBL7802445 0.79 KDM4E (0.43) KMT2AKDM4EHPGDPKMNPC1
SCHEMBL18301096 0.79 KMT2A (0.39) KMT2AKDM4EPKMNPC1RAB9A
SCHEMBL8803345 0.77 RAB9A (0.39) LY96KMT2AHTTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922400-B Muscarinic M1 receptor positive allosteric modulators 苏文生命科学有限公司 2021-05-11 CN disclosed
US-10308620-B2 Muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2019-06-04 US disclosed
US-20180155302-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2018-06-07 US disclosed
EP-3303331-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Suven Life Sciences Limited (IN) 2018-04-11 EP disclosed
WO-2016198937-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2016-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308620-B2 Muscarinic M1 receptor positive allosteric modulators CHRM1, CHRM2, CHRM3 LY96 2783/4885KMT2A 1642/4885HTT 3088/4885
US-20180155302-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CHRM2, CHRM3 LY96 2783/4885KMT2A 1642/4885HTT 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.